Naltrexone Pharmacogenetics in Alcohol-dependent Patients

CME Educational Objectives 1. Identify that naltrexone reduces risk to relapse for heavy drinking but does not influence abstinence, according to results from more than 20 double-blind, placebo-controlled trials. 2. Summarize the nature of the A118G variant on mu opioid receptor function, both in vitro and in vivo. 3. Cite that Food and Drug Administration (FDA) requirements for restricting indications to specific genotypes for naltrexone will require multiple complex clinical trials.